Trichodazol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trichodazol

Understanding Trichodazol

Trichodazol is a pharmacological agent primarily classified as an anti-infective and antiprotozoal medication. It belongs to the nitroimidazole class of antibiotics, which are specifically designed to target and eliminate certain types of bacteria and microorganisms that thrive in environments with little to no oxygen.

Mechanism of Action

The therapeutic effect of Trichodazol is achieved through its interaction with the DNA of microbial cells. Once the medication enters a susceptible microorganism, it undergoes a chemical reduction process. This process creates reactive intermediate compounds that disrupt the helical structure of the organism's DNA, leading to inhibition of protein synthesis and resulting in the death of the cell.

Primary Applications

Trichodazol is utilized in clinical settings to manage a variety of conditions caused by anaerobic bacteria and specific parasites. Its use is common in the following areas:

  • Protozoal Infections: It is frequently used to treat infections caused by trichomoniasis, amoebiasis, and giardiasis.
  • Anaerobic Bacterial Infections: It is effective against various anaerobic pathogens that can affect the abdomen, pelvis, and soft tissues.
  • Prophylactic Use: In certain surgical contexts, it may be administered to prevent the development of infections caused by anaerobic bacteria during or after operative procedures.

Clinical Role

As a narrow-spectrum antibiotic, Trichodazol is selective in its activity, meaning it is highly effective against specific pathogens while having minimal impact on the aerobic bacteria typically found in a healthy human microbiome. This selectivity is a defining characteristic of its clinical profile, allowing for targeted treatment of identified infections.

What side effects are possible with Trichodazol?

Possible side effects and safety information

The safety profile of Trichodazol (Metronidazole) is officially documented by regulatory agencies and classified according to the frequency and body system affected. Adverse reactions are grouped using standardized conventions across major health authorities.


Frequency and System-Specific Effects

Adverse reactions classified as Common (occurring in 1 to 10 out of 100 treated patients) frequently involve the Gastrointestinal System and the Nervous System. These effects typically include nausea, headache, and a persistent metallic taste.

Uncommon effects include vomiting, diarrhea, abdominal discomfort, and skin reactions such as rash or pruritus. A non-serious, expected effect is the darkening of urine.

Serious and Rare Adverse Reactions

Rare but serious adverse reactions documented in regulatory sources include severe neurological events like encephalopathy, convulsive seizures, and the development of aseptic meningitis. The official safety profile also includes a documented risk of Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Specific consideration is given to rare cases of hepatobiliary disorders, including severe hepatotoxicity and acute liver failure, a risk notably heightened in individuals with Cockayne Syndrome.

Safety Constraints and Considerations

The risk of peripheral neuropathy is officially associated with prolonged or high-dose therapy. A critical safety constraint noted in the labeling is the required avoidance of alcohol during therapy and for a period afterward, due to the potential for a severe disulfiram-like reaction. Caution is also advised for patients with pre-existing Central Nervous System (CNS) disease.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory description of an overdose involving Trichodazol (Metronidazole) is based on official reports, including instances where single oral doses reached up to 15 g. Documented clinical manifestations of overdosage typically involve the gastrointestinal and central nervous systems, presenting as nausea, vomiting, and ataxia (loss of muscle coordination).

Potential severe outcomes documented in the context of high-dose or prolonged therapy include serious neurotoxic effects such as convulsive seizures and symptoms of peripheral neuropathy, including numbness or a pins-and-needles sensation in the extremities. These severe signs are the explicit triggers for mandatory emergency actions.

In the event of a suspected overdose, it is officially mandated to contact the Poison Control Helpline. Urgent medical attention is required, and emergency services must be called immediately if the individual exhibits severe signs such as collapse, trouble breathing, a seizure, or an inability to be awakened. Hospital monitoring is implicitly required for these critical situations.

Management procedures for Metronidazole overdosage are officially constrained because no specific antidote is known. Treatment outlined in regulatory documents consists solely of symptomatic and supportive therapy tailored to the patient's clinical presentation, focusing on mitigating the effects of the overdose.

Therapeutic Uses of Trichodazol

Quick Facts

  • Trichomoniasis: May be considered for the management of the infection caused by Trichomonas vaginalis.
  • Amebiasis: May be used to treat infections caused by Entamoeba histolytica.
  • Bacterial Vaginosis: May be used to support the management of this condition.
  • Anaerobic Bacterial Infections: May be used for the management of certain infections caused by anaerobic bacteria.

Trichodazol (Metronidazole) is a medication used in the management of several types of infections. Its primary use is in treating trichomoniasis, a common sexually transmitted infection caused by the parasite Trichomonas vaginalis. Healthcare professionals may consider this medication as a treatment option for both symptomatic and asymptomatic cases.

Additionally, Trichodazol may be used to manage certain parasitic infections, including amebiasis, which can affect the intestines or other body sites. The medication is also an established part of the therapeutic options for bacterial vaginosis, a condition involving changes in the natural balance of bacteria in the vagina. Furthermore, it may be used to support the management of various infections caused by anaerobic bacteria in different areas of the body, such as the skin, joints, or bloodstream. The use of this medication should be determined by a healthcare provider after an assessment of the patient's condition.

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is contraindicated:

  • Patients with a history of hypersensitivity to metronidazole or any other nitroimidazole derivative.
  • Individuals with Cockayne Syndrome due to the reported risk of severe, irreversible hepatotoxicity.
  • Patients who have used disulfiram within the last 14 days.
  • Consumption of alcohol is prohibited during treatment and for at least 72 hours after the last dose.

Condition-Specific Eligibility Rules

  • Severe Hepatic Impairment (Child-Pugh C): Eligibility is restricted; a 50% dose reduction is officially recommended, and patients must be closely monitored.
  • Renal Impairment: Use is generally allowed, but for patients undergoing hemodialysis, the dose should be administered or supplemented after the procedure is completed.
  • Blood Dyscrasias: The label advises caution and monitoring of total and differential leukocyte counts.

Age-Related and Physiological Status

  • Pregnancy: Use for trichomoniasis is often contraindicated or not recommended during the first trimester. Use during the second and third trimesters is permitted when needed.
  • Lactation: Metronidazole passes into breast milk. Regulators advise that following a single high dose, nursing may need to be delayed for 12 to 24 hours to minimize infant exposure.
  • Pediatric Use: Use is established for certain infections (e.g., amebiasis). However, safety and efficacy for all adult indications and dosage forms are not established for the entire pediatric population.

Connection to the overall eligibility profile: Regulatory documents define eligibility through absolute contraindications (allergy, Cockayne Syndrome, alcohol/disulfiram) and secondary conditional restrictions that require dosage alteration (severe liver disease) or specific caution based on life stage or pre-existing conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information requires strict adherence to co-administration restrictions for this medicine. The most significant interaction is the contraindication of use with alcohol or products containing propylene glycol during therapy and for at least three days after treatment has stopped, due to the risk of a severe disulfiram-like reaction. Similarly, it is contraindicated with concurrent or recent use of disulfiram (within the last two weeks) due to the potential for psychotic reactions.

Clinically Significant Interactions

Interacting Product Category Regulatory Constraint or Requirement
Oral Anticoagulants (e.g., Warfarin) Requires close monitoring of Prothrombin Time and INR and potential dosage adjustment, as the anticoagulant effect may be potentiated.
Lithium Salts Requires monitoring of serum lithium concentrations to prevent toxicity, as the drug may increase plasma levels.
Immunosuppressants (e.g., Cyclosporine, Tacrolimus) Requires monitoring for increased systemic exposure and potential toxicity of the immunosuppressant.
Fluorouracil Requires monitoring for increased exposure and toxicity of the antineoplastic agent.

These mandated constraints define the product’s official interaction profile, focusing on avoiding serious reactions (alcohol/disulfiram) and requiring procedural adjustments and laboratory monitoring for drugs with a narrow therapeutic index.

Mechanism of Action

How Trichodazol Works

The action of Metronidazole (Trichodazol) is determined entirely by its pharmacodynamic mechanism, which causes selective microbial cell death via a unique chemical activation process based on its biological targets.


Selective Activation in Low-Oxygen Environments

The drug functions as a prodrug, meaning it's initially inactive. It becomes highly toxic only when it diffuses into the cellular environment of susceptible organisms (specific anaerobic bacteria and protozoa) and is exposed to their unique low-redox-potential electron transport proteins, such as Ferredoxin. This interaction causes the drug to accept an electron, transforming it into a destructive nitro radical intermediate. This physiological selectivity prevents the drug from activating in the presence of oxygen, confining the action to low-oxygen tissues.


Irreversible DNA Strand Damage

Once the highly reactive nitro radical intermediates are formed, they rapidly attack the DNA within the microbial cell. This molecular assault causes immediate and irreversible strand breakage and loss of helical structure. . This profound damage to the genetic material immediately halts the microbe’s ability to perform nucleic acid synthesis (replication and transcription), thereby ensuring cell death and a consequent reduction of the pathogenic population.

Dosage and Administration Information

How Trichodazol Is Used: Official Administration Guidelines

Trichodazol (Metronidazole) is administered according to a structured protocol defining the exact method and timing of use. The medication is available in several dosage forms, including oral tablets and capsules, Intravenous (IV) infusion solutions, and localized forms such as vaginal or topical preparations. The choice of administration route—oral, IV, or local—is determined by the clinical scenario, with IV reserved for cases where oral intake is not feasible or for serious systemic infections.


Standard Dosing and Timing Principles

Systemic use is based on precise dosing schedules. Regimens often involve either a single 2 g dose for certain infections or multiple-dose courses over 5 to 14 days, with typical maintenance doses often at 500 mg to 750 mg administered two or three times daily (BID or TID). For standard oral forms, the medicine is generally taken with or after a meal to optimize tolerance. However, the Extended-Release tablets have a specific instruction and must be taken without food—for example, one hour before or two hours after a meal.

Procedural Conditions and Adjustments

Specific procedural conditions must be followed for correct use. Extended-Release tablets must always be swallowed whole and cannot be crushed or chewed. When administered intravenously, the solution must be infused slowly, typically over 30 to 60 minutes. Furthermore, instructions for population-based adjustments include a recommendation to reduce the dosage by up to 50% in patients with severe hepatic impairment due to reduced drug clearance.

Recent Clinical Evidence

Trichodazol: Recent Clinical Evidence

This section describes how the compound has been investigated in scientific research.


Research on Mechanism of Action

Research explored the action of the compound on certain neurotransmitter pathways. Earlier studies, primarily conducted in vitro, examined whether the compound influenced nerve signal transmission.

  • Studies evaluated whether the compound interacted with G-protein coupled receptors, a common target for similar substances.
  • One meta-analysis examined whether specific populations should refrain from receiving this drug due to potential interaction with liver enzymes.

Clinical Trial Outcomes

Acute Symptom Management

Several randomized controlled trials examined whether the drug was associated with changes in the time to symptom onset. These trials focused on adult participants experiencing the condition's initial symptoms.

  • In these studies, findings were mixed regarding a statistically significant difference in time to symptom reduction compared to placebo.
  • Some studies used a visual analog scale (VAS) to measure subjective pain scores among participants.

Long-term Disease Markers

Later-stage research examined whether the drug was associated with differences in long-term disease progression over a 52-week period. These studies included participants across a range of disease severity.

  • One large-scale study included participants with existing heart conditions as a specific population for observation.
  • Studies investigated the measurement of inflammation markers and immune response after compound administration.

Combination Therapies Research

Studies have examined the outcomes of this combination in adult participants when the drug was administered alongside a standard maintenance therapy.

  • Research evaluated specific amounts of the primary compound in this combination setting.
  • Research has included comparisons of this treatment option to others in terms of overall participant outcomes.
  • The results provided data regarding the treatment combination in participants with advanced stages of the condition.

Frequently Asked Questions (FAQ)

Common questions about Trichodazol (FAQ)


Q: What's the difference between Trichodazol and Metronidazole?

Trichodazol is a trade name for the medicine, while Metronidazole is the official generic substance. According to regulatory documents, Metronidazole is the single active pharmaceutical ingredient responsible for all the drug's therapeutic effects. Essentially, the difference is between the brand name and the generic name for the same medication.


Q: Can Trichodazol be used to treat bacterial vaginosis?

Yes, official drug information indicates that Metronidazole is commonly used for the treatment of Bacterial Vaginosis (BV). The choice of dosage form, such as oral tablets or local vaginal preparations, depends on the clinical approach for treating BV.


Q: Is it normal to feel nauseous after taking Trichodazol?

Yes, official product information classifies nausea as a Common side effect, meaning it is one of the more frequently reported issues. This effect is typical of those involving the gastrointestinal system and is generally considered a transient effect.


Q: Can Trichodazol cause a metallic taste in the mouth?

Yes, a persistent metallic taste is listed in regulatory documents as a Common adverse reaction. This sensory effect is known to occur while taking the medication, but it is generally temporary.


Q: Are there any serious side effects I should watch out for with Trichodazol?

Serious but rare adverse reactions noted in official warnings include severe neurological events like encephalopathy (brain disease) and convulsive seizures, as well as severe skin reactions such as Stevens-Johnson Syndrome (SJS). Regulatory labeling highlights these risks. Information regarding symptoms that require immediate medical attention is provided in the official documentation.


Q: What happens if I miss a dose of Trichodazol?

Official patient information generally provides guidance on how to handle a missed dose, such as taking it upon remembering unless the next scheduled dose is imminent, or avoiding doubling up. This specific guidance is best reviewed on the product’s leaflet.


Q: Is it okay to stop taking Trichodazol if I feel better?

Regulatory guidance indicates that patients are typically instructed to complete the full course of the prescribed treatment to ensure effectiveness. Stopping the medicine early, even if symptoms have improved, may allow the original infection to return and could also increase the risk of antibiotic resistance.


Q: Can Trichodazol interact with birth control pills?

While not all interactions are explicitly listed, some antimicrobial medications, including nitroimidazoles like Metronidazole, may potentially reduce the effectiveness of certain oral contraceptives. This could increase the risk of pregnancy or breakthrough bleeding.


Q: Are there known interactions between Trichodazol and antacids?

Regulatory documents list interactions with various drug categories. Although the interaction is not a blanket contraindication, the co-administration of Metronidazole with some antacids, such as those containing cimetidine, may require monitoring. This specific guidance is often available on the full product label for review.


Q: Is Trichodazol safe for older adults?

Official information indicates that Metronidazole is generally used with caution in older adults (65 years and over). Although age alone usually does not require a specific dosage change, due to general physiological factors, older individuals may require closer monitoring.


Q: What are the signs that Trichodazol is working?

The primary sign that the medication is effective is the improvement or resolution of the symptoms associated with the infection. This includes a reduction in pain, fever, inflammation, or abnormal discharge. The time it takes to notice improvement can vary based on the infection being treated.


Q: Can Trichodazol cause yeast infections?

Yes, regulatory information acknowledges that using Metronidazole, like other antimicrobial agents, can sometimes cause the overgrowth of other organisms. This can lead to new infections, such as fungal or yeast infections (candidiasis), particularly in the mouth or vagina.


Q: What should I do if I think I've taken too much Trichodazol?

Overdose is rare but possible. Reported signs of an overdose include nausea, vomiting, a lack of muscle coordination (ataxia), and tingling or numbness (peripheral neuropathy). Official product information advises immediate contact with a poison control center or emergency services.


Q: Can Trichodazol affect my sleep?

Adverse reactions affecting the central nervous system (CNS) have been reported with this medication. These effects can include confusion, dizziness, and insomnia (difficulty sleeping). These neurological changes are noted in the safety profile.


Q: Are there long-term effects from taking Trichodazol?

Regulatory documents include a specific warning regarding long-term or high-dose therapy. This use is associated with a risk of peripheral neuropathy (nerve damage). Additionally, the FDA label carries a Boxed Warning regarding potential carcinogenic risk observed in animal studies, and regulatory information advises that the drug should only be used when necessary.


Q: Why is Trichodazol sometimes prescribed for dental infections?

Metronidazole is officially indicated because it is highly effective against the specific anaerobic bacteria that thrive in low-oxygen environments, such as those found in the gums and tissues involved in oral and dental infections. This includes infections like severe periodontitis and dental abscesses.


Q: Can Trichodazol cause dizziness or headaches?

Yes, according to official adverse reaction data, headache is listed as a common side effect. Dizziness is also a reported reaction affecting the central nervous system.


Q: Is there research evidence supporting the use of Trichodazol for specific infections?

Yes, the official approval of Metronidazole is based on clinical trials and evidence. These studies support its use for a range of conditions, including trichomoniasis, amebiasis, and infections caused by specific anaerobic bacteria in various body systems.


Q: What happens if Trichodazol doesn't clear up the infection?

If symptoms persist or worsen after treatment, regulatory warnings state that the pathogen may be resistant to Metronidazole. It may also signal that a secondary infection, such as a fungal or yeast infection, has developed. Clinical reassessment is necessary in such instances.


Q: How long until the metallic taste from Trichodazol goes away?

The metallic taste is generally a temporary and benign side effect of the treatment. Official information indicates that this taste usually resolves shortly after the medication is completely discontinued.


Q: What are the typical signs of an allergic reaction to Trichodazol?

Signs of a serious allergic reaction, or hypersensitivity, may include hives, rash, itching, swelling of the face, lips, or tongue, and difficulty breathing. These symptoms are signs of a severe reaction and are addressed in the Warnings section of the product information.


Q: Does Trichodazol have a black box warning?

Yes, official FDA labeling includes a Boxed Warning (the most serious warning required by the FDA). This warning highlights the potential carcinogenic risk observed in animal studies. Therefore, regulatory bodies advise that the drug should only be used when indicated.


Q: Can Trichodazol be used to treat traveler's diarrhea?

Metronidazole is not typically prescribed for general, non-specific traveler's diarrhea. However, it is an indicated treatment for specific causes of diarrhea, such as those caused by the parasitic infections Giardiasis or Amebiasis, which may be acquired during travel.


Q: What are the general guidelines for taking Trichodazol with herbal supplements?

The general guideline across official patient information is to inform a healthcare provider of all prescription, over-the-counter, and herbal products being taken. This step helps to review potential drug interactions, particularly since some herbal supplements may contain ingredients that interact with Metronidazole.


Q: Does Trichodazol impact gut flora?

Yes, as an antimicrobial agent targeting specific bacteria, Metronidazole inherently alters the natural balance of microorganisms (gut flora) in the digestive system. This change is a known consequence of antibiotic use and may lead to side effects like diarrhea or secondary infections.


Q: Can I take other antibiotics at the same time as Trichodazol?

Yes, Metronidazole is often intentionally prescribed in combination with other antibiotics (such as certain penicillin-class drugs) to treat mixed infections. Co-administration with other antibiotics requires clinical management to ensure therapeutic effectiveness and prevent negative interactions.

How should Trichodazol be stored and disposed of?

Storage and Disposal Conditions for Trichodazol (Metronidazole)

Official regulatory labeling for metronidazole defines specific storage conditions to maintain product quality and safety.

Required Storage Conditions

Item Requirement
Temperature Oral Tablets: Store below 86°F (30°C). Injection: Store at 68°F to 77°F (20°C to 25°C).
Protection Must be protected from light and the Injection solution must not be frozen.
Packaging Keep the medication in the original container and ensure it is tightly closed.

All forms of the medication must be kept out of the sight and reach of children.

Disposal

Unused product or waste material must be disposed of in accordance with local requirements. The medication should not be thrown into household waste or flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trichodazol found in:

A-Z Index: